Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis

James (Jim) Rosenbaum, Richard S. Boney

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Interleukin 1 has been implicated in intraocular inflammation. The availability of a cloned, recombinant interleukin 1 receptor antagonist has enabled us to test the role of interleukin 1 in specific models of uveitis in New Zealand white rabbits. Seventy-five micrograms of interleukin 1 receptor antagonist injected intravitreally resulted in a 97% reduction in aqueous humor cells present 6 hours after intravitreal injection of 10 ng of human interleukin 1 α. Disruption of the blood aqueous barrier was prevented by the receptor antagonist (mean SD aqueous humor protein of 0.6±0.1 g/L in rabbits treated with interleukin 1 receptor antagonist vs 32.2±9.9 g/L in controls). Lower doses of interleukin 1 produced more modest but significant inhibition. Despite the activity of interleukin 1 receptor antagonist in inhibiting interleukin 1-induced inflammation, interleukin 1 receptor antagonist did not produce significant reduction in inflammation subsequent to an active Arthus reaction or subsequent to the intravitreal injection of 125 ng of endotoxin. A potential explanation of these observations is that cytokines in addition to interleukin 1 may be present in sufficient quantities to produce intraocular inflammation or that the effects of interleukin 1 may be primarily intracellular (intracrine) and therefore resistant to the activity of exogenously administered receptor antagonist.

Original languageEnglish (US)
Pages (from-to)547-549
Number of pages3
JournalArchives of Ophthalmology
Volume110
Issue number4
DOIs
StatePublished - 1992

Fingerprint

Interleukin-1 Receptors
Uveitis
Interleukin-1
Rabbits
Inflammation
Intravitreal Injections
Aqueous Humor
Arthus Reaction
Blood-Aqueous Barrier
Endotoxins
Cytokines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis. / Rosenbaum, James (Jim); Boney, Richard S.

In: Archives of Ophthalmology, Vol. 110, No. 4, 1992, p. 547-549.

Research output: Contribution to journalArticle

@article{7262208839914890a94f080e5e415209,
title = "Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis",
abstract = "Interleukin 1 has been implicated in intraocular inflammation. The availability of a cloned, recombinant interleukin 1 receptor antagonist has enabled us to test the role of interleukin 1 in specific models of uveitis in New Zealand white rabbits. Seventy-five micrograms of interleukin 1 receptor antagonist injected intravitreally resulted in a 97{\%} reduction in aqueous humor cells present 6 hours after intravitreal injection of 10 ng of human interleukin 1 α. Disruption of the blood aqueous barrier was prevented by the receptor antagonist (mean SD aqueous humor protein of 0.6±0.1 g/L in rabbits treated with interleukin 1 receptor antagonist vs 32.2±9.9 g/L in controls). Lower doses of interleukin 1 produced more modest but significant inhibition. Despite the activity of interleukin 1 receptor antagonist in inhibiting interleukin 1-induced inflammation, interleukin 1 receptor antagonist did not produce significant reduction in inflammation subsequent to an active Arthus reaction or subsequent to the intravitreal injection of 125 ng of endotoxin. A potential explanation of these observations is that cytokines in addition to interleukin 1 may be present in sufficient quantities to produce intraocular inflammation or that the effects of interleukin 1 may be primarily intracellular (intracrine) and therefore resistant to the activity of exogenously administered receptor antagonist.",
author = "Rosenbaum, {James (Jim)} and Boney, {Richard S.}",
year = "1992",
doi = "10.1001/archopht.1992.01080160125049",
language = "English (US)",
volume = "110",
pages = "547--549",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis

AU - Rosenbaum, James (Jim)

AU - Boney, Richard S.

PY - 1992

Y1 - 1992

N2 - Interleukin 1 has been implicated in intraocular inflammation. The availability of a cloned, recombinant interleukin 1 receptor antagonist has enabled us to test the role of interleukin 1 in specific models of uveitis in New Zealand white rabbits. Seventy-five micrograms of interleukin 1 receptor antagonist injected intravitreally resulted in a 97% reduction in aqueous humor cells present 6 hours after intravitreal injection of 10 ng of human interleukin 1 α. Disruption of the blood aqueous barrier was prevented by the receptor antagonist (mean SD aqueous humor protein of 0.6±0.1 g/L in rabbits treated with interleukin 1 receptor antagonist vs 32.2±9.9 g/L in controls). Lower doses of interleukin 1 produced more modest but significant inhibition. Despite the activity of interleukin 1 receptor antagonist in inhibiting interleukin 1-induced inflammation, interleukin 1 receptor antagonist did not produce significant reduction in inflammation subsequent to an active Arthus reaction or subsequent to the intravitreal injection of 125 ng of endotoxin. A potential explanation of these observations is that cytokines in addition to interleukin 1 may be present in sufficient quantities to produce intraocular inflammation or that the effects of interleukin 1 may be primarily intracellular (intracrine) and therefore resistant to the activity of exogenously administered receptor antagonist.

AB - Interleukin 1 has been implicated in intraocular inflammation. The availability of a cloned, recombinant interleukin 1 receptor antagonist has enabled us to test the role of interleukin 1 in specific models of uveitis in New Zealand white rabbits. Seventy-five micrograms of interleukin 1 receptor antagonist injected intravitreally resulted in a 97% reduction in aqueous humor cells present 6 hours after intravitreal injection of 10 ng of human interleukin 1 α. Disruption of the blood aqueous barrier was prevented by the receptor antagonist (mean SD aqueous humor protein of 0.6±0.1 g/L in rabbits treated with interleukin 1 receptor antagonist vs 32.2±9.9 g/L in controls). Lower doses of interleukin 1 produced more modest but significant inhibition. Despite the activity of interleukin 1 receptor antagonist in inhibiting interleukin 1-induced inflammation, interleukin 1 receptor antagonist did not produce significant reduction in inflammation subsequent to an active Arthus reaction or subsequent to the intravitreal injection of 125 ng of endotoxin. A potential explanation of these observations is that cytokines in addition to interleukin 1 may be present in sufficient quantities to produce intraocular inflammation or that the effects of interleukin 1 may be primarily intracellular (intracrine) and therefore resistant to the activity of exogenously administered receptor antagonist.

UR - http://www.scopus.com/inward/record.url?scp=0026552420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026552420&partnerID=8YFLogxK

U2 - 10.1001/archopht.1992.01080160125049

DO - 10.1001/archopht.1992.01080160125049

M3 - Article

C2 - 1532889

AN - SCOPUS:0026552420

VL - 110

SP - 547

EP - 549

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 4

ER -